Growth-hormone and metabolic peptides studied for muscle and fat changes
Building muscle while losing fat depends largely on two signalling systems: the growth-hormone axis, which supports lean tissue and fat breakdown, and appetite and fat-metabolism pathways that reduce stored fat. The compounds below act at different points in these systems, and the strength of evidence varies widely. Some have human trial data in specific patient groups; others rest mainly on animal work or practitioner reports.
1The biology of this goal
Your body composition — how much of you is muscle versus fat — is shaped by hormone signals. Growth hormone, made by a gland at the base of the brain called the pituitary, tells the body to build and preserve muscle and to break down fat. The liver responds to growth hormone by making another signal, IGF-1, that drives tissue growth. A second set of signals controls hunger and how fat is stored or burned: gut and pancreas hormones tell the brain you are full and tell fat cells whether to release or hold onto fat. The peptides here nudge one or both of these systems — some prompt the body to release more of its own growth hormone, some act directly on fat cells, and some reduce appetite.
Human trials report that sermorelin stimulates the body's own growth hormone secretion and is used to treat growth hormone deficiency in children.
Sermorelin is a lab-made copy of the active part of the body's own growth hormone-releasing hormone (GHRH). Instead of supplying growth hormone directly, it signals the pituitary gland to make and release its own growth hormone in natural bursts, which then prompts the liver to make IGF-1. Because it works within normal feedback loops, growth hormone release stays pulsatile.
Sermorelin is a 29-amino-acid analogue of human GHRH and the shortest synthetic peptide with full GHRH biological activity, specifically stimulating growth hormone secretion from the anterior pituitary.1
Once-daily subcutaneous sermorelin at 30 micrograms/kg at bedtime was effective in treating some prepubertal children with idiopathic growth hormone deficiency.1
Sermorelin is described as causing release of growth hormone from the pituitary gland, which is necessary for growth.3
Growth hormone secretagogues have been developed to treat growth hormone deficiency, which causes altered body composition among other effects.2
What this doesn't establish
The clinical evidence here concerns diagnosis and treatment of growth hormone deficiency in children; it does not establish muscle gain or fat loss as a body-composition outcome in healthy adults.
Human trials report sustained IGF-1 elevation with MK-677, though the lean-mass evidence for body composition comes only from a single co-administration case report at animal-and-lab tier.
MK-677 (ibutamoren) is a pill-form molecule that mimics the hunger hormone ghrelin. It switches on the ghrelin receptor in the pituitary and hypothalamus, prompting the body to release more of its own growth hormone, which raises IGF-1. Because it survives digestion, it can be taken by mouth once daily and keeps growth hormone and IGF-1 raised for up to about 24 hours.
MK-677 is a non-peptide, orally active growth hormone secretagogue and potent GHSR1a agonist that sustains GH and IGF-1 elevation for up to 24 hours from a single daily dose.4
Average IGF-1 elevation of 40–89% has been documented across clinical trials with sustained effects during chronic administration.4
In a single case report, MK-677 co-administered with LGD-4033 for 5 weeks increased total lean body mass by 3.1% and appendicular lean body mass by 4.3%, but total fat mass rose 15.4%.5
Reported side effects of MK-677 include oedema, increased appetite and muscle pain, and a case of transaminitis (liver enzyme elevation) that resolved after stopping.6
What this doesn't establish
The lean-mass gains reported were measured when MK-677 was combined with the anabolic drug LGD-4033 in one individual, so they cannot be attributed to MK-677 alone; fat mass actually rose in that report.
Human Phase 1 trials report sustained, dose-dependent increases in GH and IGF-1 after CJC-1295, with the increased-muscle-mass claim drawn from a regulatory presentation.
CJC-1295 is a long-acting synthetic version of growth-hormone-releasing hormone (GHRH). It prompts the pituitary to release the body's own growth hormone, raising IGF-1, while amplifying the natural pulsing pattern rather than replacing it. A modified version binds a blood protein to extend its active life to about a week.
Subcutaneous CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1 levels in Phase 1 trials in healthy adults.7
A regulatory presentation lists increased muscle mass/strength and improved GH and IGF-1 among CJC-1295's reported effects.7
CJC-1295 amplifies the existing pulsatile GH secretion pattern; a single 60 μg/kg dose produced IGF-1 elevations lasting up to 14 days, with accumulation on repeated weekly dosing.8
Phase II clinical development of CJC-1295 DAC was discontinued following the death of a trial participant, reportedly from a cardiovascular event.8
What this doesn't establish
The GH/IGF-1 pharmacodynamic data are solid, but direct measured muscle-gain or fat-loss outcomes in trials are not established here, and clinical development of the DAC form was discontinued after a participant death reportedly from a cardiovascular event.
Human trials report that tesamorelin reduces visceral fat and improves trunk fat and waist circumference in HIV-associated lipodystrophy.
Tesamorelin is a stabilized synthetic copy of growth hormone-releasing hormone (GHRH). It prompts the body to release its own growth hormone in a natural pulsing pattern, which drives the liver to make IGF-1 and promotes fat breakdown. It is the one compound here approved specifically to reduce deep abdominal fat, in HIV patients with lipodystrophy.
Subcutaneous tesamorelin reduced visceral adipose tissue in two 26-week trials in HIV-associated central fat accumulation, with improvements in trunk fat and waist circumference; visceral fat reaccumulated after discontinuation.11
Tesamorelin activates pituitary GHRH receptors, leading to GH release that stimulates hepatic production of IGF-1, and raises IGF-1 levels such that monitoring is recommended.10
Tesamorelin increased growth hormone levels in healthy subjects and raised IGF-1 dose-dependently in healthy subjects and in HIV-infected patients.12
Most serious adverse events were injection-site reactions or GH-associated events such as arthralgia, headache and peripheral edema.11
What this doesn't establish
The efficacy data are specific to HIV-associated visceral fat accumulation and to fat reduction, not to muscle building, and discontinuing therapy led to reaccumulation of visceral fat.
Human trials report dose-dependent weight loss of roughly 15–24% with retatrutide, alongside a significant loss of lean mass.
Retatrutide is a single peptide that switches on three gut and metabolic hormone receptors at once. This reduces appetite, slows stomach emptying, and increases energy burned, producing substantial weight loss. It is injected once weekly.
Retatrutide, a GLP-1/GIP/glucagon triple agonist, induces approximately 15–24% weight loss in adults with overweight and obesity.15
Retatrutide also causes rapid and significant loss of lean mass of about 10% (~6 kg), comparable to a decade or more of aging.15
Targeting the glucagon receptor increases energy expenditure, suppresses appetite and enhances fat metabolism while improving glycaemic control.13
Animal studies show retatrutide delays gastric emptying, reduces food intake and promotes weight loss, and Phase I and II trials show dose-dependent weight loss.14
What this doesn't establish
For this goal the crucial caveat is that retatrutide causes rapid, significant lean-mass loss (~10% or ~6 kg) along with fat loss — it reduces fat but does not build muscle, and lean-mass preservation depends on resistance exercise.
Animal and gene-therapy studies suggest that follistatin overexpression substantially increases skeletal muscle mass and reduces body fat, with the peptide-injection evidence resting on lower-tier community and practitioner sources.
Follistatin is a natural protein that acts as a 'blocker' of muscle-limiting signals. It grabs and neutralizes myostatin and activin A — proteins that normally put the brakes on muscle growth. Removing that brake allowed muscles to grow larger in animal and gene-therapy studies.
Mice engineered to overexpress follistatin in muscle had at least twice the skeletal muscle mass of controls, and transgenic pigs showed increased skeletal muscle and reduced body fat with a higher lean-meat percentage (72.95% vs 69.18%).16
Transgenic pigs showed myofiber hypertrophy and significantly reduced Smad2 phosphorylation in skeletal muscle.16
Practitioner sources describe follistatin physically wrapping around myostatin at high affinity to prevent it reaching its ActRIIB receptor, and report that a single AAV-delivered dose produced sustained muscle-mass increases exceeding 20% in mice.17
Follistatin expression in skeletal muscle is upregulated by resistance exercise and mechanical loading, and myostatin deficiency across species produces increased muscle mass and reduced adiposity.18
What this doesn't establish
There are no human trials establishing that injecting the short-lived follistatin-344 peptide builds muscle or reduces fat; the striking results come from genetic overexpression or AAV gene therapy that keeps follistatin present continuously.
Human trials report a substantial, dose-dependent growth-hormone release after intravenous hexarelin.
Hexarelin is a synthetic six-amino-acid peptide that mimics the hunger hormone ghrelin. It binds the ghrelin receptor on the pituitary to trigger a strong, pulsing release of growth hormone. In human studies the growth-hormone rise was clear and dose-dependent.
Intravenous hexarelin produced substantial, dose-dependent growth hormone release, with mean peak concentrations of 3.9, 26.9, 52.3 and 55.0 ng/ml after 0, 0.5, 1 and 2 μg/kg.21,19
Plasma GH peaked at about 30 minutes and returned to baseline within 240 minutes, with a half-life of about 55 minutes.21,20
Plasma glucose, LH, FSH, TSH and IGF-1 were unaffected by hexarelin, while it caused a slight increase in prolactin, cortisol and ACTH.21
What this doesn't establish
The human data show acute GH release only; IGF-1 was unaffected in the single-dose study, and no trial here links hexarelin to muscle gain or fat loss as a body-composition outcome.
Human trials report clinically significant, dose-dependent weight loss with once-weekly cagrilintide.
Cagrilintide is a long-acting synthetic version of amylin, a hormone the pancreas releases with insulin after meals to signal fullness. It activates amylin receptors in the brain to reduce appetite and increase the feeling of being full, producing weight loss. It is injected once weekly.
Once-weekly cagrilintide produced clinically significant, dose-dependent weight loss greater than placebo at all doses, and at 4.5 mg produced greater weight loss than liraglutide 3.0 mg.22
Cagrilintide is an amylin analogue whose satiating effect, combined with a GLP-1 receptor agonist, shows an additive effect on appetite reduction.23
Completed phase 2 trials on incretin-based therapies (including amylin agonist components) showed mean weight loss of 7.4% to 24.2%, with CagriSema in ongoing phase 3 trials.24
What this doesn't establish
Cagrilintide's evidence is for appetite-driven weight loss; it does not address muscle building, and the trials do not separate fat loss from lean-mass loss for this goal.
Animal and laboratory studies suggest ipamorelin selectively stimulates growth hormone release without raising other pituitary hormones.
Ipamorelin is a synthetic five-amino-acid peptide that mimics the hunger hormone ghrelin. It switches on the ghrelin receptor in the pituitary to trigger a pulse of growth hormone. What sets it apart, according to these sources, is selectivity: in animal studies it released growth hormone without raising cortisol, prolactin or other pituitary hormones.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that stimulates GH release by activating GHSR-1a (the ghrelin receptor) in the pituitary and hypothalamus.25,26
In preclinical studies ipamorelin stimulated GH with potency comparable to GHRP-6 but without significant increases in ACTH, cortisol, prolactin, TSH or the gonadotropins.25,26
Ipamorelin amplifies pulsatile GH secretion rather than producing a tonic elevation.26
As a ghrelin receptor agonist, ipamorelin mimics ghrelin's actions in stimulating GH secretion, within a class developed to treat GH deficiency that causes altered body composition.27
What this doesn't establish
The evidence is preclinical and from vendor/educational profiles; there is no human trial here demonstrating muscle gain or fat loss, and downstream body-composition effects remain inferred rather than measured.
Animal and laboratory studies suggest MOTS-c enhances glucose metabolism and insulin sensitivity and leads to weight loss in mice.
MOTS-c is a small peptide encoded inside mitochondria, the cell's power plants, and is described as a signal of mitochondrial health. Its main studied action is switching on AMPK, a cellular energy sensor that tells cells to burn fuel more efficiently and resist storing fat. Because exercise raises MOTS-c and it reproduces exercise-like effects in animals, it is often called an 'exercise-mimetic.'
MOTS-c is a mitochondrial-derived peptide that targets skeletal muscle, enhances glucose metabolism, and activated insulin sensitivity in the skeletal muscle of diabetic mice.28
Acute high-intensity exercise in humans increases MOTS-c concentrations in skeletal muscle and plasma, and MOTS-c treatment leads to weight loss in mice with adaptations similar to being physically active.29
A small Phase 1a/1b study of a MOTS-c analogue was well tolerated with reductions in liver enzymes and glucose and a trend toward weight loss, while animal studies show prevention of muscle atrophy and enhanced muscle insulin sensitivity.30
What this doesn't establish
Human clinical evidence is extremely limited — one small 4-week trial of a MOTS-c analogue — so fat-loss benefit in people is unproven, and there is no evidence it builds muscle.
Animal and laboratory studies suggest AOD-9604 induces weight loss and increases lipolytic sensitivity in obese mice.
AOD-9604 is a small synthetic peptide copied from the tail end of human growth hormone — the part thought to be responsible for growth hormone's fat-burning activity. It was designed to encourage fat breakdown and reduce new fat formation without raising blood sugar or IGF-1. Unlike full growth hormone, it does not meaningfully bind the growth hormone receptor.
AOD-9604 induced weight loss and increased lipolytic sensitivity after long-term treatment in obese mice, and raised repressed beta-3 adrenergic receptor RNA to levels comparable with lean mice.31,32
In beta-3-AR knockout mice, long-term AOD-9604 failed to change body weight or increase lipolysis, but acutely still increased energy expenditure and fat oxidation, indicating its action is not directly mediated by the beta-3-AR.31,32
AOD-9604 is described as selectively stimulating lipolysis and inhibiting lipogenesis in adipose tissue without activating the hGH receptor, raising IGF-1, or impairing glucose metabolism.33
What this doesn't establish
The controlled efficacy evidence here is from mouse models; the human trial claims come from a lower-tier vendor source, and no evidence establishes muscle building.
These compounds split into families. The GHRH analogues (sermorelin, CJC-1295, tesamorelin) all hit the same GHRH receptor, so combining them is largely redundant — you would generally choose one, with tesamorelin the visceral-fat specialist. The ghrelin-receptor secretagogues (ipamorelin, hexarelin, MK-677) likewise share the GHS-R1a receptor and are redundant with each other; MK-677's appetite stimulation and fluid retention can also work against a fat-loss goal. The well-known synergy is pairing a GHRH-side driver with a ghrelin-side one — for example ipamorelin with sermorelin, CJC-1295, or tesamorelin — because the two receptors reinforce each other for a larger GH pulse while keeping release pulsatile. Follistatin-344 builds muscle through myostatin blockade, an entirely separate route from GH/IGF-1, so it is complementary to the secretagogues rather than overlapping. On the fat-loss side, AOD-9604 acts directly on fat cells and can complement GH-driven approaches or MOTS-c's oxidation pathway without receptor competition. Cagrilintide and retatrutide both drive appetite-based weight loss and are largely redundant with each other; retatrutide's notable lean-mass loss is where an anabolic or GH-axis agent might be paired, though direct data for these combinations are thin. Several pairings in this list have no documented interaction data at all, which is an absence of evidence rather than a guarantee of safety.
Ipamorelin + Hexarelin
Worth caution — see why below
Both hexarelin and ipamorelin are growth hormone secretagogues that switch on the exact same pituitary receptor (GHS-R1a) to trigger a GH pulse, so stacking them is largely redundant rather than additive — you're pushing the same button twice. The key difference is selectivity: hexarelin also raises ACTH, cortisol and prolactin and blunts (desensitizes) with continued use, whereas ipamorelin gives a cleaner GH pulse without those extra hormones. For most goals you'd choose one, and ipamorelin is the cleaner GHS-R1a option.
Ipamorelin + MK-677
Worth caution — see why below
MK-677 (ibutamoren) is an oral non-peptide that hits the same ghrelin receptor (GHS-R1a) as ipamorelin. Running both means competing for the identical receptor and GH-release pathway, so the effect is redundant rather than additive. MK-677 also produces a long, sustained receptor activation plus notable appetite stimulation and water retention — layering ipamorelin on top adds little extra GH while compounding those side effects. Most people should use one GHS-R1a agonist, not two.
Hexarelin + MK-677
Worth caution — see why below
MK-677 is an oral ghrelin-mimetic that hits the same GHS-R1a receptor hexarelin does. Combining them is redundant — both compete for and desensitize the same receptor — and MK-677's long half-life keeps that receptor occupied around the clock, which can blunt the pulse a short-acting injectable like hexarelin is trying to create. Pick one GHS-R1a agonist rather than layering two.
Hexarelin + CJC-1295
Worth caution — see why below
Hexarelin is a ghrelin-receptor (GHS-R1a) agonist, a different upstream mechanism from CJC-1295's GHRH receptor. The two converge on greater GH secretion, so combining amplitude (GHRH) with a secretagogue can be additive. Note hexarelin also stimulates ACTH/cortisol and prolactin and can desensitize its receptor over time, so it's less selective than ipamorelin.
MK-677 + AOD-9604
Worth caution — see why below
MK-677 raises GH/IGF-1 (which can support lipolysis) but also markedly stimulates appetite and can promote fluid retention, potentially working against AOD-9604's fat-loss goal. Worth understanding the appetite trade-off before combining.
MK-677 + Tesamorelin
Worth caution — see why below
Tesamorelin is a stabilized GHRH analog that raises GH/IGF-1 through the GHRH receptor, distinct from MK-677's ghrelin-receptor pathway. Both feed the same GH/IGF-1 axis, so they can be additive on GH output. Note a practical tension: tesamorelin is used specifically to reduce visceral fat, whereas MK-677 raises appetite and can promote fluid retention and insulin resistance, which may partly counter the body-composition goal.
MK-677 + CJC-1295
Worth caution — see why below
MK-677 is an oral ghrelin-receptor agonist that raises GH/IGF-1 via a different receptor than CJC-1295. The mechanisms are complementary (pulse amplitude from GHRH vs. secretagogue-driven pulses), but because MK-677 produces sustained IGF-1 elevation, combining the two can push IGF-1 high — monitor levels and watch for water retention/appetite effects.
MK-677 + Cagrilintide
Worth caution — see why below
MK-677 is a ghrelin-receptor agonist that reliably INCREASES appetite, which directly opposes cagrilintide's core action of suppressing appetite and increasing satiety. Running them together works against your weight-management goal and can blunt cagrilintide's benefit.
MOTS-c + Follistatin-344
Worth caution — see why below
MOTS-c is reported to regulate myostatin through a CK2-PTEN-mTORC2-AKT-FOXO1 axis, converging on the same muscle-limiting signal that Follistatin neutralizes directly. Both also add metabolic/anti-inflammatory benefits, so they may reinforce each other on body composition, though this convergence is only weakly characterized.
What the research doesn't establish
Follistatin-344 acts directly on myostatin/GDF-8, sequestering the ligand and blocking SMAD2/3 signaling; MOTS-c has no comparable direct action, and its influence on myostatin—if any—would be indirect via a CK2-PTEN-mTORC2-AKT-FOXO1 route that is not established as a primary mechanism. Their anti-inflammatory effects also arise through different pathways (TGF-beta antagonism versus Keap1-Nrf2 and AMPK), so a shared muscle-limiting target is not demonstrated.
Follistatin-344 + CJC-1295
Worth caution — see why below
Follistatin-344 builds muscle by blocking myostatin/activin (disinhibiting mTOR/Akt), an entirely different mechanism from CJC-1295's GH/IGF-1 elevation. Both converge on protein synthesis and lean mass, so they can be complementary for body-composition goals via independent pathways.
Sermorelin + Tesamorelin
Worth caution — see why below
Tesamorelin is also a GHRH-receptor agonist working through the identical Gs/cAMP pathway to release endogenous GH. Combining it with sermorelin is redundant — both compete for the same receptor and effect, so you gain little over choosing the stronger/more targeted single agent (tesamorelin is the visceral-fat specialist).
Sermorelin + CJC-1295
Worth caution — see why below
Both are GHRH analogs that hit the exact same receptor (GHRH-R) on pituitary somatotrophs to trigger the cAMP-driven GH pulse. Stacking them is redundant rather than additive — you'd just be doubling up on one mechanism. CJC-1295 is longer-acting than sermorelin, so most people choose one or the other rather than combining.
Sermorelin + Retatrutide
Worth caution — see why below
Sermorelin raises endogenous GH (and IGF-1) via the GHRH receptor, promoting lipolysis and lean-mass preservation. This is a distinct mechanism from retatrutide and can help offset the lean-mass loss that often accompanies rapid incretin-driven weight loss, making it a complementary pairing. Monitor blood sugar as GH can modestly raise insulin resistance.
Tesamorelin + CJC-1295
Worth caution — see why below
Tesamorelin is also a stabilized GHRH analog acting on the same GHRH-R/cAMP pathway to raise GH and IGF-1. Combining it with CJC-1295 stacks two drugs doing the identical job, which is redundant and could over-drive IGF-1 without adding a distinct benefit. Choose one GHRH agent for a given goal.
Tesamorelin + Retatrutide
Worth caution — see why below
Tesamorelin reduces visceral and hepatic fat by stimulating endogenous growth hormone (GHRH-receptor pathway) — a completely different route from retatrutide's receptor set, yet both reduce liver/visceral fat and improve lipids. They converge on the same physiological output (fat reduction) via separate upstream mechanisms, making them complementary; monitor glucose since GH can nudge insulin resistance while retatrutide improves it.
Cagrilintide + Retatrutide
Worth caution — see why below
Both potently reduce appetite and body weight, but through different receptors — cagrilintide via amylin/calcitonin receptors and retatrutide via triple GIP/GLP-1/glucagon agonism. Combining two maximally effective weight-loss agents is largely redundant and stacks the same side effects (nausea, delayed gastric emptying, appetite loss), so this is more a choose-one situation than an additive stack.
Ipamorelin + AOD-9604
May be complementary
AOD-9604 drives fat mobilization through a GH-independent route (beta-3 adrenergic/HSL activation, not the GH receptor), while ipamorelin promotes lipolysis indirectly via GH release. Because they hit fat metabolism from different directions and both ultimately raise cAMP-driven hormone-sensitive lipase activity, they can be used together for fat-loss goals without receptor competition.
Ipamorelin + Sermorelin
May be complementary
Sermorelin is a GHRH-receptor agonist, a different upstream pathway from ipamorelin's ghrelin receptor, but both feed into the same GH/IGF-1 axis. Pairing a GHRH analog with a ghrelin-receptor agonist is the well-known two-pronged strategy: sermorelin drives GHRH-side signaling while ipamorelin adds the ghrelin-side push and blunts somatostatin, giving a bigger combined GH pulse while keeping the release pulsatile.
Ipamorelin + Tesamorelin
May be complementary
Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor — a distinct mechanism from ipamorelin's ghrelin receptor — but both raise GH/IGF-1 and support fat loss. Combining a GHRH-side driver with ipamorelin's ghrelin-side amplification produces a larger GH pulse, and tesamorelin's specific strength in reducing visceral fat can complement ipamorelin's reported lipolysis for body-composition goals.
Ipamorelin + CJC-1295
May be complementary
Ipamorelin works through a different receptor (the ghrelin/GHS-R1a receptor) than CJC-1295's GHRH-R. GHRH analogs increase the size of each GH pulse while ghrelin-mimetics increase pulse frequency and suppress somatostatin — so the two amplify each other's GH release. This GHRH + GHRP pairing is the classic synergistic GH stack.
Hexarelin + Follistatin-344
May be complementary
Hexarelin raises IGF-1 and, notably, suppresses TGF-beta driven fibrosis — overlapping with Follistatin's own anti-fibrotic, muscle-sparing action. One works through GH/IGF-1, the other through myostatin/activin blockade, so they converge on healthier, larger muscle through different routes.
Hexarelin + Sermorelin
May be complementary
Sermorelin is a GHRH-receptor agonist and hexarelin is a GHS-R1a agonist — two different receptors that feed the same GH secretory pathway. Pairing a GHRH analog with a ghrelin-mimetic secretagogue is a well-established synergistic strategy: the GHRH signal and the secretagogue signal reinforce each other for a bigger pulse than either produces alone.
Hexarelin + Tesamorelin
May be complementary
Tesamorelin is a stabilized GHRH analog; hexarelin is a GHS-R1a secretagogue. They act on distinct receptors that both drive pituitary GH release, so combined they can produce a larger, more physiologic GH/IGF-1 response — with tesamorelin adding a documented visceral-fat-lowering effect. Monitor IGF-1 since two upstream drivers stacking can push it higher than intended.
MK-677 + Follistatin-344
May be complementary
MK-677 elevates GH/IGF-1 and improves nitrogen balance, supporting protein synthesis from the anabolic-hormone side, while Follistatin releases the myostatin brake. The two attack muscle growth from separate angles, making them additive rather than redundant.
MK-677 + Sermorelin
May be complementary
Sermorelin is a GHRH-receptor agonist, a different upstream trigger from MK-677's ghrelin-receptor action, yet both raise pulsatile GH and IGF-1 and both are reported to deepen slow-wave sleep. Using a GHRH signal plus a ghrelin-mimetic can enhance the GH pulse more than either alone, and their overlapping sleep benefits reinforce each other.
MOTS-c + AOD-9604
May be complementary
MOTS-c improves fat metabolism and drives fat oxidation/adipose browning via AMPK and mitochondrial signaling, while AOD-9604 mobilizes fat by raising cAMP and activating hormone-sensitive lipase. Mobilization (AOD) plus enhanced oxidation (MOTS-c) are logically complementary steps of the same fat-loss process.
AOD-9604 + Sermorelin
May be complementary
Sermorelin drives fat loss indirectly by prompting the pituitary to release more of the body's own growth hormone, whereas AOD-9604 acts directly on fat cells to trigger lipolysis. Different upstream triggers converging on the same fat-burning outcome make them potentially additive rather than redundant.
AOD-9604 + Tesamorelin
May be complementary
Both push fat loss but by different routes: tesamorelin raises endogenous growth hormone via the GHRH receptor, while AOD-9604 stimulates fat breakdown directly in fat cells (cAMP rise, hormone-sensitive lipase) without acting on the GH receptor. Because their entry points differ, they can reinforce each other on the same goal of reducing (especially visceral) fat.
AOD-9604 + CJC-1295
May be complementary
CJC-1295 boosts GH (and downstream IGF-1) through the GHRH receptor, a hormone-mediated path to fat mobilization, while AOD-9604 stimulates lipolysis directly at the adipocyte. The two hit fat loss from different directions and are not redundant with each other.
Follistatin-344 + Sermorelin
May be complementary
Sermorelin boosts the body's own GH/IGF-1 output to support lean mass, whereas Follistatin drives hypertrophy by neutralizing myostatin. Different upstream mechanisms converge on the same goal of building muscle, so they complement rather than duplicate each other.
Follistatin-344 + Tesamorelin
May be complementary
Tesamorelin raises GH/IGF-1 and preferentially strips visceral fat, while Follistatin adds muscle mass and reduces adiposity by blocking myostatin. Their combined effect leans toward improved body composition (more lean mass, less fat) through distinct pathways.
MOTS-c + Tesamorelin
No known conflict in the research
Both reduce adiposity, especially visceral and hepatic fat, but through unrelated mechanisms: tesamorelin raises GH/IGF-1 to drive lipolysis, while MOTS-c acts through AMPK-driven metabolism and adipose browning. These non-overlapping fat-loss pathways can complement each other for body-composition goals.
MOTS-c + Retatrutide
No known conflict in the research
MOTS-c is a mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity and promotes fat oxidation/adipose browning — a metabolic mechanism entirely separate from retatrutide's gut-hormone receptors. Both push toward improved glucose handling and fat loss, so they complement each other on the same metabolic goal via different pathways.
AOD-9604 + Retatrutide
No known conflict in the research
AOD-9604 mobilizes fat by upregulating beta-3 adrenergic/hormone-sensitive-lipase driven lipolysis and inhibiting lipogenesis, a distinct mechanism from retatrutide's incretin/glucagon-driven appetite and energy-expenditure effects. Both converge on reduced fat mass, so they are complementary for a fat-loss goal, though evidence for the combination specifically is anecdotal.
21 other pairings have no documented interaction in our data — that is not a safety clearance.
Ipamorelin + MOTS-c
Ipamorelin + Follistatin-344
Ipamorelin + Cagrilintide
Ipamorelin + Retatrutide
Hexarelin + MOTS-c
Hexarelin + AOD-9604
Hexarelin + Cagrilintide
Hexarelin + Retatrutide
MK-677 + MOTS-c
MK-677 + Retatrutide
MOTS-c + Sermorelin
MOTS-c + CJC-1295
MOTS-c + Cagrilintide
AOD-9604 + Follistatin-344
AOD-9604 + Cagrilintide
Follistatin-344 + Cagrilintide
Follistatin-344 + Retatrutide
Sermorelin + Cagrilintide
Tesamorelin + Cagrilintide
CJC-1295 + Cagrilintide
CJC-1295 + Retatrutide
4Related but not studied for this goal
These share some of this goal's biology and are not off-target — but their research is elsewhere: on the skin, or on another condition. Listed so you know we saw them.
Melanotan II shares appetite and satiety with this goal, but only 4 of its 193 research claims mention build muscle and lose fat; it has not been studied for it.
Alpha-MSH shares appetite and satiety with this goal, but only 6 of its 155 research claims mention build muscle and lose fat; it has not been studied for it.
5Compounds we looked at and left out
These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.
Semaglutide is linked to fat breakdown, but in this compound that activity is about appetite suppression and reduced caloric intake for weight loss.
“It also acts on appetite regulation and slows the rate at which the stomach empties, leading to reduced food intake and weight loss.”— from its own profile
This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.
See something wrong or out of date on this page? Report it.